Fatigue and symptom-based clusters in post COVID-19 patients: a multicentre, prospective, observational cohort study.

Department of Pulmonary Medicine, Amsterdam UMC, Amsterdam, The Netherlands. m.e.b.cornelissen@amsterdamumc.nl. Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, The Netherlands. m.e.b.cornelissen@amsterdamumc.nl. Amsterdam Public Health Research Institute, Amsterdam UMC, Amsterdam, The Netherlands. m.e.b.cornelissen@amsterdamumc.nl. Department of Pulmonary Medicine, Amsterdam UMC, Amsterdam, The Netherlands. Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, The Netherlands. Amsterdam Public Health Research Institute, Amsterdam UMC, Amsterdam, The Netherlands. Department of Research and Development, Ciro, Horn, The Netherlands. Department of Respiratory Medicine, Nutrim Institute of Nutrition and Translational Research in Metabolism, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands. Department of Environmental Epidemiology, Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands.

Journal of translational medicine. 2024;(1):191
Full text from:

Abstract

BACKGROUND In the Netherlands, the prevalence of post COVID-19 condition is estimated at 12.7% at 90-150 days after SARS-CoV-2 infection. This study aimed to determine the occurrence of fatigue and other symptoms, to assess how many patients meet the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) criteria, to identify symptom-based clusters within the P4O2 COVID-19 cohort and to compare these clusters with clusters in a ME/CFS cohort. METHODS In this multicentre, prospective, observational cohort in the Netherlands, 95 post COVID-19 patients aged 40-65 years were included. Data collection at 3-6 months after infection included demographics, medical history, questionnaires, and a medical examination. Follow-up assessments occurred 9-12 months later, where the same data were collected. Fatigue was determined with the Fatigue Severity Scale (FSS), a score of ≥ 4 means moderate to high fatigue. The frequency and severity of other symptoms and the percentage of patients that meet the ME/CFS criteria were assessed using the DePaul Symptom Questionnaire-2 (DSQ-2). A self-organizing map was used to visualize the clustering of patients based on severity and frequency of 79 symptoms. In a previous study, 337 Dutch ME/CFS patients were clustered based on their symptom scores. The symptom scores of post COVID-19 patients were applied to these clusters to examine whether the same or different clusters were found. RESULTS According to the FSS, fatigue was reported by 75.9% of the patients at 3-6 months after infection and by 57.1% of the patients 9-12 months later. Post-exertional malaise, sleep disturbances, pain, and neurocognitive symptoms were also frequently reported, according to the DSQ-2. Over half of the patients (52.7%) met the Fukuda criteria for ME/CFS, while fewer patients met other ME/CFS definitions. Clustering revealed specific symptom patterns and showed that post COVID-19 patients occurred in 11 of the clusters that have been observed in the ME/CFS cohort, where 2 clusters had > 10 patients. CONCLUSIONS This study shows persistent fatigue and diverse symptomatology in post COVID-19 patients, up to 12-18 months after SARS-CoV-2 infection. Clustering showed that post COVID-19 patients occurred in 11 of the clusters that have been observed in the ME/CFS cohort.

Methodological quality

Publication Type : Observational Study ; Multicenter Study

Metadata